Russian new generation therapeutic antiseptic drug

The history of the Miramistin® medication development brings us back to the 80s, when a group of scientists led by Doctor of Medical Sciences, Professor Yu.S. Krivoshein, within the framework of the Space Biotechnology program, developed a drug belonging to the class of surfactants and intended for use as a means of personal protection for astronauts in orbital stations.Wide spectrum of antimicrobial action and absolute harmlessness was the top requirement for the medication. The synthesis of the active molecule and production of the substance were carried out by Ph.D. Adolina Petrovna Rudko, who is also considered one of the medication composers. The new synthesized molecule was given a working title BH-14.

Clinical testing of the medication was facilitated by the Olympics in Moscow. The permission to speed up the clinical trials of BH-14 right before the Olympics-80 was personally recommended by the Minister of Health Boris Petrovsky. Scientists and doctors did a great job and clinically proved that the future Miramistin® is effective for prophylaxis against most of the known pathogens of sexually transmitted diseases. One of the most effective medications reputation meant preventing STI infection capability. It has been entrenched in Miramistin® for many years.

The USSR collapse leads to Russian scientific potential reduction, but the medication composers continued scientific research due to private investments. Russian Ministry of Health officially registered a new drug for prevention and treatment of sexually transmitted diseases (Order of the Ministry of Health No. 139 of May 31, 1991) after conducting a series of clinical trials. At that time, the future Miramistin® was called "Infacept"

A trial batch was released on the basis of an interhospital pharmacy of the medical center of the Administrative Department of the President of Russia. Infacept first appeared in Moscow pharmacies and the first batch was small – about 30 thousand bottles. Permission received from the Ministry of Health of Russia allowed to use a wide spectrum as an antiseptic and carry out the first trial sales of the medication through distributors.

Miramistin® brand inceptionNew packaging presentation Clinical trials at the departments of the Crimean State Medical University conducted in various fields: otolaryngology, obstetrics and gynecology, combustiology, gastroenterology. In particular, a study the in infectious diseases in otorhinolaryngology medication strength was carried out. At the same time strength of the medication was studied burn wounds of various degrees and area of ​​damage prevention of suppuration in the early stages after injury on the basis of the Scientific Research Institute of Emergency Medicine. N.V. Sklifosovsky using Miramistin®.

Pharmacological properties comprehensive additional studies of Miramistin® showed that it stimulates reparative processes and has an immunomodulatory effect alongside with antimicrobial properties. Driven by numerous studies carried out in more than 20 medical centers in Russia and other countries, including the Main Military Clinical Hospital. N.N.Burdenko, Central Research Institute of Traumatology and Orthopedics named after N.N. Priorov, Research Institute of Surgery. A.V.Vishnevsky Russian Academy of Medical Sciences, the Central Research Institute of Skin and Venereal Diseases of the Ministry of Health of the Russian Federation, the Medical Center of the Presidential Administration of the Russian Federation, the Central Hospital of the Ministry of Internal Affairs of the Russian Federation, the clinical efficacy and safety of Miramistin® in various fields of medicine have been confirmed. The drug entered various diseases treatment standards as a broad-spectrum antiseptic medication.

Miramistin® received the first award as The Best Domestic OTC Drug at the 2005 Platinum Ounce Award Ceremony

Registration and certification of new forms of issue based on Miramistin®. First foreign investments in China, India and the EU countries markets

Pharmaceutical plant launch in the city of Bagrationovsk, Kaliningrad region in accordance with GMP standards, new forms of issue formulization, international registration of the medication in the EU, additional preclinical and clinical trials performance.